Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD133+ Stem Cells with TMR in Chronic Ischemic Heart Disease
NCT03043742Phase 1Completed
- Start
- Jul 2016
- Primary completion
- Nov 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous CD133+ cells in chronic ischemic heart disease (CIHD). Primary endpoint: Treatment-emergent serious adverse events (SAE) and adverse events at 12 months. Started Jul 2016; status: completed.
02
Drugs
autologous CD133+ cells
03
Conditions
chronic ischemic heart disease (CIHD)
Beyond the preview
Go deeper on NCT03043742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03043742.